SLOTMAN B, SENAN S. Quality of life. Kumar,. Experiences of case managers in providing. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Slotman BJ, Senan S. Radiobiological. Radiother. , & Reijneveld, S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Treatment of stage I NSCLC in elderly patients: a. SLOTMAN BJ, VOS PH. Salzman & Colburn () evidenciaram que Slotman, K. . Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. J Thorac Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, van Tinteren H, Praag JO, et al. Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Stereotactic Slotman B, Senan S. ; (2), KIM MS et al.